K Number
K024336
Device Name
MIIG II BONE GRAFT SUBSTITUTE
Date Cleared
2003-03-04

(67 days)

Product Code
Regulation Number
888.3045
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The MIIG™ paste is intended to be injected into open bone voids/gaps that are not intrinsic to the stability of bony structure of the skeletal system (i.e., the extremittes, spine, and pelvis) and to cure in-situ. These open bone voids may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The MIIGM paste provides a bone void filler that resorbs and is replaced with bone during the healing process. The MIIG™ paste cured in situ provides an open void/gap filler that can augment provisional hardware (e.g., K-Wires) to help support bone fragments during the surgical procedure. The cured paste acts only as a temporary support media and is not intended to provide structural support during the healing process. The MIIG™M II is provided sterile for single use only.
Device Description
The MIIGTM II paste consists of pre-measured surgical grade calcium sulfate, premeasured mixing solution, and the tools necessary to the components into a paste and inject the material into the defect site. These products are provided sterile for single patient use. When mixed and injected according to directions. MIIG™ II paste will harden in situ and provide temporary intra-operative support to a site prior to the fixation of final hardware. The MIIGTM II product has been developed to address the identical indications as the MIIGTM product.
More Information

Not Found

Not Found

No
The summary describes a bone void filler paste and its intended use and composition. There is no mention of any software, algorithms, or data processing that would indicate the use of AI or ML.

Yes
The device is a bone void filler that resorbs and is replaced with bone during the healing process, and provides temporary intra-operative support, indicating a therapeutic function.

No

The device is a bone void filler and temporary support media, not a device used to identify or analyze medical conditions or diseases.

No

The device description clearly states it is a paste consisting of physical components (calcium sulfate, mixing solution, tools) intended for injection into bone voids, indicating it is a physical medical device, not software.

Based on the provided text, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
  • Device Function: The MIIG™ paste is a bone void filler that is injected directly into the body (in vivo) to fill gaps in bone and provide temporary support. It is a surgical implant/material, not a diagnostic test performed on a sample outside the body.

The description clearly states its intended use is for filling bone voids in situ (in the body) and providing temporary support during surgery. This is a therapeutic/surgical device, not a diagnostic one.

N/A

Intended Use / Indications for Use

The MIIGTM paste is intended to be injected into open bone voids/gaps that are not intrinsic to the stability of bony structure of the skeletal system (i.e., the extremittes, spine, and pelvis) and to cure in-situ. These open bone voids may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The MIIGM paste provides a bone void filler that resorbs and is replaced with bone during the healing process.

The MIIGTM paste cured in situ provides an open void/gap filler that can augment provisional hardware (e.g., K-Wires) to help support bone fragments during the surgical procedure. The cured paste acts only as a temporary support media and is not intended to provide structural support during the healing process.

The MIIGTM II is provided sterile for single use only.

Product codes (comma separated list FDA assigned to the subject device)

MQV

Device Description

The MIIGTM II paste consists of pre-measured surgical grade calcium sulfate, premeasured mixing solution, and the tools necessary to the components into a paste and inject the material into the defect site. These products are provided sterile for single patient use. When mixed and injected according to directions. MIIG™ II paste will harden in situ and provide temporary intra-operative support to a site prior to the fixation of final hardware. The MIIGTM II product has been developed to address the identical indications as the MIIGTM product.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Skeletal system (i.e., the extremittes, spine, and pelvis)

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Not Found

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.

Not Found

Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).

Not Found

§ 888.3045 Resorbable calcium salt bone void filler device.

(a)
Identification. A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.

0

K024336

Image /page/0/Picture/1 description: The image shows the logo for Wright Medical Technology. The logo consists of a stylized "W" formed by three black triangles, followed by the words "WRIGHT MEDICAL TECHNOLOGY" stacked on top of each other. A registered trademark symbol is located at the bottom left of the "W" symbol. A horizontal line is located underneath the text.

MAR 0 4 2003

A Wright Medical Group Company

510(K) SUMMARY OF SAFETY AND EFFECTIVENESS

In accordance with the Food and Drug Administration Rule to implement provisions of the Safe Medical Devices Act of 1990 and in conformance with 21 CRF 807, this information serves as a Summary of Safety and Effectiveness for the use of the MIIG™ II.

Submitted By:Wright Medical Technology, Inc.
Date:February 22, 2001
Contact Person:Ehab M. Esmail
Manager, Regulatory Affairs
Phone: 901-867-4732 Fax: 901-867 4630
Proprietary Name:MIIG TM II
Common Name:Bone Void Filler
Classification Name and Reference:Unclassified
Device Product Code and Panel Code:Orthopedics/87/MOV

DEVICE INFORMATION

INTENDED USES/ INDICATIONS A.

The MIIG™ paste is intended to be injected into open bone voids/gaps that are not intrinsic to the stability of bony structure of the skeletal system (i.e., the extremittes, spine, and pelvis) and to cure in-situ. These open bone voids may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The MIIGM paste provides a bone void filler that resorbs and is replaced with bone during the healing process.

The MIIG™ paste cured in situ provides an open void/gap filler that can augment provisional hardware (e.g., K-Wires) to help support bone fragments during the surgical procedure. The cured paste acts only as a temporary support media and is not intended to provide structural support during the healing process.

The MIIG™M II is provided sterile for single use only.

Image /page/0/Picture/12 description: The image shows the logo for Wright Medical Technology. The logo consists of a stylized "W" on the left, followed by the words "WRIGHT MEDICAL TECHNOLOGY" stacked on top of each other. Below the logo is the text "A Wright Medical Group Company".

Image /page/0/Picture/13 description: The image shows the text '510(K) SUMMARY.doc'. The text is in a serif font and is black. The image appears to be a document or file name.

Image /page/0/Picture/14 description: The image shows a black and white drawing of a globe. The globe is partially shaded, with the darker areas likely representing landmasses or geographical features. A curved line is visible above the globe, possibly indicating an atmospheric layer or a celestial arc. The bottom of the globe is cut off by the edge of the image.

1

B. DEVICE DESCRIPTION

The MIIGTM II paste consists of pre-measured surgical grade calcium sulfate, premeasured mixing solution, and the tools necessary to the components into a paste and inject the material into the defect site. These products are provided sterile for single patient use. When mixed and injected according to directions. MIIG™ II paste will harden in situ and provide temporary intra-operative support to a site prior to the fixation of final hardware. The MIIGTM II product has been developed to address the identical indications as the MIIGTM product.

C. MATERIALS

The materials used for the MIIG™ II are substantially equivalent to the previously submitted and cleared MIIGTM.

MIIGTMMIIGTM II
POWDERMIIGTM PowderMIIGTM II Powder
Surgical Grade Calcium Sulfate Hemihydrate Accelerator Setting AdditiveSurgical Grade Calcium Sulfate Hemihydrate Accelerator
LIQUIDDiluentDiluent
Saline IrrigationSterile Water for Irrigation

SUBSTANTIAL EQUIVALENCE INFORMATION D.

The intended use, material composition, and design features of the MIIGTM II are substantially equivalent to the intended use, material composition, and design features of the previously submitted and cleared MIIG.

The safety and effectiveness of the MIIGTM II is adequately supported by the substantial equivalence information, materials data, and testing results provided within this Premarket Notification.

Image /page/1/Picture/9 description: The image is a logo for Wright Medical Technology. The logo features a stylized "W" on the left, followed by the words "WRIGHT MEDICAL TECHNOLOGY" stacked on top of each other. Below a horizontal line, the text "A Wright Medical Group Company" is present.

Image /page/1/Picture/10 description: The image shows a black and white photograph of what appears to be a cell or a planet. The object is circular with a dark upper right portion and a lighter, textured area in the lower left. There is a small, dark object near the center of the lighter area, and a small, dark line at the bottom of the image.

2

Image /page/2/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States of America. The seal features a stylized eagle with its wings spread, symbolizing protection and service. Encircling the eagle is the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA", indicating the department's name and national affiliation.

Public Health Service

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAR 0 4 2003

Mr. Ehab M. Esmail Manager, Regulatory Affairs Wright Medical Technology, Inc. 5677 Airline Road Arlington, TN 38002

Re: K024336

Trade/Device Name: MIIG™ II Regulatory Class: Unclassified Product Code: MQV Dated: February 11, 2003 Received: February 12, 2003

Dear Mr. Esmail:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

3

Page 2 - Mr. Ehab M. Esmail

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Mark N Milken

Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

4

Image /page/4/Picture/0 description: The image shows the logo for Wright Medical Technology. The logo consists of a stylized "W" on the left, followed by the words "WRIGHT MEDICAL" stacked on top of "TECHNOLOGY" on the right. The "W" is made up of three thick, black, angled lines, and the text is in a simple, sans-serif font.

A Wright Medical Group Company

MIIGTM II

INDICATIONS STATEMENT

The MIIG™ paste is intended to be injected into open bone voids/gaps that are not intrinsic to the stability of bony structure of the skeletal system (i.e., the extremities, spine, and pelvis) and to cure in-situ. These open bone voids may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The MIIG™ paste provides a bone void filler that resorbs and is replaced with bone during the healing process.

The MIIGM paste cured in situ provides an open void/gap filler that can augment provisional hardware (e.g., K-Wires) to help support bone fragments during the surgical procedure. The cured paste acts only as a temporary support media and is not intended to provide structural support during the healing process.

The MIIGTM is provided sterile for single use only.

R. Mark McMillenn
Division Sign-Off

Sign-Off Division of Gene I, Restorative and Nearological Devices

510(k) Number K024336

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off) Division of General Restorative Devices 510(k) Number

Prescription Use V (Per21 CFR 801.109) OR

Over-The Counter Use (Optional Format 1-2-96)

Image /page/4/Picture/16 description: The image shows the logo for Wright Medical Technology. The logo consists of a large, stylized "W" on the left, followed by the words "WRIGHT MEDICAL TECHNOLOGY" stacked on top of each other. Below the logo is the text "A Wright Medical Group Company."

Image /page/4/Picture/17 description: The image shows a black and white drawing of a celestial body, possibly a planet or moon. The object has a textured surface with varying shades of gray and black, suggesting craters or other geological features. A bright, curved line is visible at the top, possibly indicating an atmosphere or ring system. The overall impression is that of a distant, somewhat desolate world.

INDICATIONS STATEMENT.doc